Biotechnology company Imago BioSciences has expanded its global Phase IIb clinical study evaluating bomedemstat (IMG-7289) into Hong Kong.
Bomedemstat is an inhibitor of lysine-specific demethylase 1 (LSD1) and is used to treat advanced myelofibrosis (MF).
For this trial, the first patient has been dosed at the Department of Medicine, Queen Mary Hospital and the University of Hong Kong.
Discovered and developed by Imago BioSciences, bomedemstat is an orally available small molecule.
LSD1 is an enzyme vital for self-renewal of malignant myeloid cells and the differentiation of myeloid progenitors.
A rare bone marrow cancer, MF interferes with blood cell production.
Apart from Hong Kong, the study is enrolling patients in the US, UK, and EU, and is in the final stages of concluding enrolment to evaluate the safety, tolerability and efficacy of the drug.
Imago BioSciences CEO Hugh Rienhoff said: “We are progressing well with enrollment and are pleased to continue expanding our global Phase II study into new geographies like Hong Kong.
“We are encouraged by the signs of clinical activity and safety of bomedemstat as a treatment alternative for patients who do not benefit from the current standards of care.”
Preliminary data from the ongoing study showed that the LSD1 inhibitor was well tolerated with no dose-limiting toxicities or safety signals.
In July this year, bomedemstat received PRIority Medicines (PRIME) designation from the European Medicines Agency (EMA) for treating MF.
In addition, the therapy is being analysed in two open-label Phase II clinical trials for the treatment of advanced MF and essential thrombocythemia (ET).
The EMA reviewed non-clinical and clinical data of bomedemstat from the ongoing Phase II study, which showed improvements in symptom scores, spleen volumes, anaemia, and bone marrow fibrosis.